Kalaris Therapeutics
KLRS4.1603.70% ( -0.160 )
Kalaris Therapeutics (KLRS)
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal dis...
- Open
- 4.380
- High
- 4.380
- Low
- 4.160
- Prev. Close
- 4.320
- Volume
- 8.21K
- Turnover
- 35.31K
- Avg Price
- 4.300
- Bid/Ask Ratio
- --
- Amplitude
- 5.09%
- 52wk High
- 11.880
- Volume Ratio
- 0.17
- Turnover Ratio
- 0.11%
Kalaris Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$18.71360.72%
Forecast & RatingBuy
8analysts
- Strong buy62.50%
- Buy25.00%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 day ago, 01:20 AM
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% - Here's What Happened
- PUBT · 1 day ago, 03:02 PM
Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statement
- PUBT · Jul 27 at 03:05 PM
Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statement
- PUBT · Jul 20 at 03:59 PM
Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko
- TradingView · Jul 20 at 07:13 AM
Kalaris names Liisa Bayko CFO and Amy Vandekop interim principal accounting officer
- Tip Ranks · Jul 17 at 12:08 PM
Why Is Penny Stock Kalaris Therapeutics (KLRS) Up Today?
